TScan Therapeutics, Inc. to Post Q1 2024 Earnings of ($0.27) Per Share, Wedbush Forecasts (NASDAQ:TCRX)

TScan Therapeutics, Inc. (NASDAQ:TCRXFree Report) – Wedbush cut their Q1 2024 earnings per share (EPS) estimates for TScan Therapeutics in a research note issued to investors on Wednesday, April 17th. Wedbush analyst D. Nierengarten now expects that the company will earn ($0.27) per share for the quarter, down from their prior estimate of ($0.26). Wedbush has a “Outperform” rating and a $10.00 price objective on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.03) per share. Wedbush also issued estimates for TScan Therapeutics’ Q2 2024 earnings at ($0.23) EPS, Q3 2024 earnings at ($0.24) EPS, Q4 2024 earnings at ($0.25) EPS, FY2024 earnings at ($0.98) EPS, FY2025 earnings at ($1.08) EPS, FY2026 earnings at ($1.13) EPS and FY2027 earnings at ($0.91) EPS.

TScan Therapeutics (NASDAQ:TCRXGet Free Report) last posted its quarterly earnings data on Wednesday, March 6th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.08. TScan Therapeutics had a negative return on equity of 60.65% and a negative net margin of 423.86%. The firm had revenue of $7.21 million for the quarter, compared to the consensus estimate of $2.94 million.

Separately, HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of TScan Therapeutics in a research note on Thursday, March 7th.

Read Our Latest Report on TScan Therapeutics

TScan Therapeutics Stock Down 1.4 %

Shares of TCRX opened at $6.82 on Friday. The business’s 50 day moving average is $7.06 and its 200 day moving average is $5.69. The company has a market capitalization of $326.54 million, a PE ratio of -3.61 and a beta of 0.90. TScan Therapeutics has a 12-month low of $1.62 and a 12-month high of $9.00. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.18.

Hedge Funds Weigh In On TScan Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Millennium Management LLC purchased a new position in TScan Therapeutics during the 4th quarter valued at approximately $31,000. Jane Street Group LLC purchased a new position in TScan Therapeutics during the 2nd quarter valued at approximately $32,000. Renaissance Technologies LLC purchased a new position in TScan Therapeutics during the 1st quarter valued at approximately $37,000. Pale Fire Capital SE purchased a new position in shares of TScan Therapeutics in the 3rd quarter worth approximately $42,000. Finally, American Century Companies Inc. purchased a new position in shares of TScan Therapeutics in the 3rd quarter worth approximately $49,000. Hedge funds and other institutional investors own 82.83% of the company’s stock.

About TScan Therapeutics

(Get Free Report)

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.

Read More

Earnings History and Estimates for TScan Therapeutics (NASDAQ:TCRX)

Receive News & Ratings for TScan Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TScan Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.